Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis
2019-000895-40Phase 3Completed
- Sponsor
- Aarhus University Hospital
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of salbutamol in myasthenia gravis (MG), sponsored by Aarhus University Hospital. Primary endpoint: Change in MG-QOL15 score. Started Feb 2019; status: completed.
02
Drugs
salbutamol
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2019-000895-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000895-40.